Your browser doesn't support javascript.
loading
Hypertrophic obstructive cardiomyopathy.
Veselka, Josef; Anavekar, Nandan S; Charron, Philippe.
  • Veselka J; Department of Cardiology, 2nd Medical School, Charles University and Motol University Hospital, Prague, Czech Republic. Electronic address: veselka.josef@seznam.cz.
  • Anavekar NS; Departments of Cardiology and Radiology, Mayo Clinic, Rochester, MN, USA.
  • Charron P; Université Paris Sud, UVSQ, INSERM U1018, CESP, Boulogne-Billancourt, France; APHP, ICAN, Hôpital de la Pitié Salpêtrière, Paris, France.
Lancet ; 389(10075): 1253-1267, 2017 03 25.
Article en En | MEDLINE | ID: mdl-27912983
ABSTRACT
Hypertrophic obstructive cardiomyopathy is an inherited myocardial disease defined by cardiac hypertrophy (wall thickness ≥15 mm) that is not explained by abnormal loading conditions, and left ventricular obstruction greater than or equal to 30 mm Hg. Typical symptoms include dyspnoea, chest pain, palpitations, and syncope. The diagnosis is usually suspected on clinical examination and confirmed by imaging. Some patients are at increased risk of sudden cardiac death, heart failure, and atrial fibrillation. Patients with an increased risk of sudden cardiac death undergo cardioverter-defibrillator implantation; in patients with severe symptoms related to ventricular obstruction, septal reduction therapy (myectomy or alcohol septal ablation) is recommended. Life-long anticoagulation is indicated after the first episode of atrial fibrillation.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Cardiomiopatía Hipertrófica Tipo de estudio: Etiology_studies / Prognostic_studies Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Cardiomiopatía Hipertrófica Tipo de estudio: Etiology_studies / Prognostic_studies Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article